Leo Pharma A/S researchers have synthesized new interleukin-17 (IL-17) modulators reported to be useful for the treatment of psoriasis, psoriatic arthritis, spondyloarthritis, radiographic ankylosing spondylitis (ankylosing spondylitis) and autoimmune diseases.
Research at RIKEN has led to the identification of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer and viral infections.
Phosphatidylinositol 3-kinase α (PI3Kα) inhibitors have been reported in a Synnovation Therapeutics Inc. patent as useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Zig Therapeutics Inc. reported on new patented systems and methods for the remote diagnosis and treatment of a bacterial infection in individuals with chronic respiratory diseases experiencing acute respiratory exacerbations using automated color vision sputum analysis.
Patent challenges for radiotherapy equipment might not make the splash that in vitro diagnostic patents have, but Elekta AB and Zap Surgical Inc., have been locked in a dispute over an Elekta patent for the past four years.
Orexia Therapeutics Ltd. has identified bicyclic-heterocycle derivatives acting as orexin OX2 receptor agonists. As such, they are reported to be useful for the treatment of narcolepsy, circadian rhythm disorder, genetic disorders, coma, metabolic syndrome, neurodegeneration, osteoporosis and sleep apnea, among others.
Research at Kinnate Biopharma Inc. has led to the development of mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.
Aromatic ring-substituted methoxy derivatives have been described in a Shanghai Yingli Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of liver and stomach cancer.
RSS
